Abraham Joseph R, Boss Joseph, Babiuch Amy S, Singh Rishi P, Srivastava Sunil, Reese Jamie, Ehlers Justis P
The Tony and Leona Campane Center for Excellence for Image-Guided Surgery and Advanced Imaging Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Vitreoretinal Service, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
J Vitreoretin Dis. 2020 Aug 19;5(1):40-45. doi: 10.1177/2474126420943418. eCollection 2021 Jan-Feb.
This work evaluated the longitudinal dynamics of ellipsoid zone (EZ) integrity in retinal vein occlusion (RVO) with macular edema and their relation to outcomes.
Clinical characteristics and optical coherence tomography data of patients with RVO and associated macular edema were collected at baseline and at 3 and 12 months. Macular cube scans were exported into EZ and retinal-layer analysis software. Longitudinal EZ parameters and visual acuity (VA) outcomes were regressed and correlated.
The study included 108 eyes of 108 patients; all eyes were treated with antivascular endothelial growth factor therapy at the baseline visit. VA improved from 20/97 at baseline to 20/52 at 3 months and 12 months ( < .001), correlating with EZ integrity at each time point ( < .001). At 12 months following initiation of antivascular endothelial growth factor therapy, EZ partial attenuation and EZ total attenuation improved over 12 months from 16.4% to 8.5% ( < .001) and from 12.3% to 5.9% ( < .001), respectively. VA improvement from baseline to 12 months correlated with improvement of EZ partial and total attenuation ( < .001). Baseline EZ characteristics did not predict VA outcomes, but at 3 months, EZ parameters did predict improvement in visual outcomes by 12 months ( < .01).
EZ and outer retinal integrity are correlated with functional outcomes in RVO. Following treatment, EZ integrity improves and is associated with functional improvement. In RVO baseline, EZ features were not associated with 1-year VA outcomes, but evaluation of EZ integrity at 3 months was linked to 1-year outcomes.
本研究评估了伴有黄斑水肿的视网膜静脉阻塞（RVO）患者椭球体带（EZ）完整性的纵向变化及其与预后的关系。
收集RVO合并黄斑水肿患者在基线、3个月和12个月时的临床特征及光学相干断层扫描数据。黄斑区容积扫描图像被导入EZ及视网膜层分析软件。对EZ的纵向参数和视力（VA）预后进行回归分析和相关性分析。
本研究纳入了108例患者的108只眼；所有患眼在基线检查时均接受了抗血管内皮生长因子治疗。视力从基线时的20/97提高到3个月和12个月时的20/52（P<0.001），且在每个时间点均与EZ完整性相关（P<0.001）。在开始抗血管内皮生长因子治疗后的12个月，EZ部分衰减和EZ完全衰减在12个月内分别从16.4%改善至8.5%（P<0.001）和从12.3%改善至5.9%（P<0.001）。从基线到12个月的视力改善与EZ部分和完全衰减的改善相关（P<0.001）。基线EZ特征不能预测视力预后，但在3个月时，EZ参数可预测12个月时视力预后的改善情况（P<0.01）。
EZ和视网膜外层完整性与RVO的功能预后相关。治疗后，EZ完整性改善并与功能改善相关。在RVO基线时，EZ特征与1年视力预后无关，但3个月时EZ完整性评估与1年预后相关。
